Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-17

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

NCT04819347

HIV/AIDS

UNKNOWN PHASE2

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

NCT04560569

HIV/AIDS

UNKNOWN PHASE2

Test Albuvirtide in Experienced Patients

NCT02369965

HIV Infections AIDS

COMPLETED PHASE3

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.

NCT01237444

HIV Infection

COMPLETED PHASE3

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574

Acquired Immunodeficiency Syndrome HIV Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a three-part, multicenter study that will enroll a total of 80 eligible, HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy. The study will be conducted in three parts.

Part 1 and Part 2 are the dose-ranging portions of the study. In Part 1, 30 eligible subjects will be randomized in a 1:1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 or continue on the existing ART regimen under one of the three cohorts as follows:

* Cohort 1: albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
* Cohort 2: albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
* Control Arm 1: Subjects continuing on baseline ART

In Part 2 of the study, 20 eligible subjects will be randomized in a 1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 under one of the two cohorts as follows:

* Cohort 3: albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
* Cohort 4: albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks

Part 3 of this study will enroll an additional 30 subjects in a 2:1 ratio to receive up to 28 weeks of combination treatment with optimal dose of albuvirtide and 3BNC117 or continue on the existing ART regimen as follows:

* Optimal Dose: albuvirtide and 3BNC11 every 2 or 4 weeks
* Control Arm 2: Subjects continuing on baseline ART All consenting patients, in Cohort 1 and 2 (Part 1) and Cohort 3 and 4 (Part 2) of the study, will be shifted from daily oral combination antiretroviral regimen to an intravenous infusion of ABT and 3BNC117. The total treatmentduration with the ABT and 3BNC117 combination regimen will be up to 16 weeks (for Part 1 and Part 2) or 28 weeks (for Part 3) with a two week overlap of the baseline oral antiretroviral regimen and the ABT-3BNC117 combination regimen at the beginning of the study treatment and at the end of the treatment phase in subjects who do not experience virologic rebound. During the two week overlap of baseline oral antiretrovirals and ABT-3BNC117 combination regimen at the beginning of the study treatment, subject will receive weekly doses of ABT and 3BNC117 as intravenous infusions. Beyond the overlap period, subjects in Cohort 1 will receive study treatments every two weeks and subjects in Cohort 2, 3, and 4 will receive study treatments every four weeks.

Study participants will be monitored for viral rebound every two weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virologic rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive blood draws.

Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: albuvirtide & 3BNC117

albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks

Group Type EXPERIMENTAL

Albuvirtide

Intervention Type DRUG

Intravenous infusion of Albuvirtide

3BNC117

Intervention Type DRUG

Intravenous infusion of 3BNC117

Cohort 2: albuvirtide & 3BNC117

albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks

Group Type EXPERIMENTAL

Albuvirtide

Intervention Type DRUG

Intravenous infusion of Albuvirtide

3BNC117

Intervention Type DRUG

Intravenous infusion of 3BNC117

Control Arm 1: Baseline ART

Subjects continuing on baseline ART

Group Type ACTIVE_COMPARATOR

Baseline ART

Intervention Type DRUG

Subjects continuing on baseline ART

Cohort 3: albuvirtide & 3BNC117

albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks

Group Type EXPERIMENTAL

Albuvirtide

Intervention Type DRUG

Intravenous infusion of Albuvirtide

3BNC117

Intervention Type DRUG

Intravenous infusion of 3BNC117

Cohort 4: albuvirtide & 3BNC117

albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks

Group Type EXPERIMENTAL

Albuvirtide

Intervention Type DRUG

Intravenous infusion of Albuvirtide

3BNC117

Intervention Type DRUG

Intravenous infusion of 3BNC117

Optimal Dose: albuvirtide & 3BNC117

albuvirtide and 3BNC117 every 2 or 4 weeks

Group Type EXPERIMENTAL

Albuvirtide

Intervention Type DRUG

Intravenous infusion of Albuvirtide

3BNC117

Intervention Type DRUG

Intravenous infusion of 3BNC117

Control Arm 2: Baseline ART

Subjects continuing on baseline ART

Group Type ACTIVE_COMPARATOR

Baseline ART

Intervention Type DRUG

Subjects continuing on baseline ART

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albuvirtide

Intravenous infusion of Albuvirtide

Intervention Type DRUG

3BNC117

Intravenous infusion of 3BNC117

Intervention Type DRUG

Baseline ART

Subjects continuing on baseline ART

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fusion inhibitor Monoclonal antibody ART

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Potential subjects are required to meet all of the following criteria for enrollment into the study.

1. HIV-1 seropositive;
2. Males and females, age ≥18 years;
3. Receiving oral combination antiretroviral therapy for last 24 weeks;
4. No change in antiretroviral regimen within last 4 weeks prior to Screening Visit and in-between Screening Visit and First Treatment Visit with an exception that subjects on NNRTI-containing regimens will be allowed to switch to protease inhibitor- or integrase strand transferase inhibitor-based regimens and such change, if needed, should occur at least 4 weeks prior to cessation of oral antiretroviral therapy;
5. Subject has two or more potential alternative antiretroviral drug options available;
6. Plasma HIV-1 RNA \<50 copies/mL at Screening Visit as determined by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR);
7. No documented detectable viral loads (HIV-1 RNA \> 50 copies/mL) within the last 24 weeks prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA \<400 copies/mL) can be considered, although the preceding and following HIV-1 RNA measurements should be \<50 copies/mL;
8. CD4 cell count of \>300 cells/mm3 at Screening Visit;
9. Laboratory values at Screening:

1. Absolute neutrophil count (ANC) ≥750/ mm3;
2. Hemoglobin (Hb) ≥10.5 gm/dL (male) or ≥9.5 gm/dL (female);
3. Platelets ≥75,000 /mm3;
4. Serum alanine transaminase (SGPT/ALT) \<1.25 x upper limit of normal (ULN);
5. Serum aspartate transaminase (SGOT/AST) \<1.25 x ULN;
6. Serum total bilirubin within normal range; and
7. Creatinine ≤1.5 x ULN.
10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator;
11. Both male and female subjects and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized or who do not have sex with women). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug;
12. Willing and able to participate in all aspects of the study, including use of intravenous medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.

Exclusion Criteria

* Potential subjects meeting any of the following criteria will be excluded from enrollment.

1. Any active infection or malignancy requiring acute therapy;
2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg);
3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening;
4. Grade 4 DAIDS laboratory abnormality;
5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study;
6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose;
7. Any vaccination within 2 weeks prior to the first study dose;
8. Subjects weighing \<35kg;
9. History of anaphylaxis to any oral or parenteral drugs;
10. Use of any fusion inhibitors and broadly neutralizing monoclonal antibody prior to the Screening Visit;
11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit;
12. Any known allergy or antibodies to the study drug or excipients;
13. Treatment with any of the following:

1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit;
2. Immunosuppressants or immunomodulating agents within 60 days prior to the screening visit; or
3. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy \> 5 mg/day will be excluded with the following exception:

* Subjects on inhaled, nasal, or topical steroids will not be excluded.
14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No